Sofosbuvir and ABT-450: Terminator of hepatitis C virus?

doi:10.3748/wjg.v19.i21.3199

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 21

This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8124)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-6) series.

Item

Count

PDF

455

HTML

5029

Figures (1-1)

153

Tables (1-6)

148

Sum=5785

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1232

Download

1107

Sum=2339

Jun 7, 2013 (publication date) through May 9, 2024

Times Cited of This Article

Times Cited (17)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jun 7, 2013; 19(21): 3199-3206
Published online Jun 7, 2013. doi: 10.3748/wjg.v19.i21.3199

Table 2 Overview of 95 hepatitis C patients under sofosbuvir regimen

Group	n	Genotype (n)	Status before treatment	Therapeutic schedule	SVR rate
1	10	2/3 (4/6)	Untreated	Sofosbuvir + RBV 12 wk	100%
2	9	2/3 (3/6)	Untreated	(Sofosbuvir + RBV 12 wk) + pegIFNα-2a 4 wk	100%
3	10	2/3 (4/6)	Untreated	(Sofosbuvir + RBV 12 wk) + pegIFNα-2a 8 wk	100%
4	11	2/3 (4/7)	Untreated	Sofosbuvir + RBV + pegIFNα-2a 12 wk	100%
5	10	2/3 (3/7)	Untreated	Sofosbuvir 12 wk	60%
6	10	2/3 (0/10)	Untreated	Sofosbuvir + RBV + pegIFNα-2a 8 wk	100%
7	10	1a/1b (9/1)	No response to prior therapy	Sofosbuvir + RBV 12 wk	10%
8	25	1a/1b (22/3)	Untreated	Sofosbuvir + RBV 12 wk	84%

The dose of sofosbuvir is 400 mg (qd), peginterferon-α (pegIFN-α)-2a is 180 μg (qw), ribavirin (RBV) is 500 mg (bid) for patients with body weight < 75 kg, and RBV is 600 mg (bid) for patients with body weight > 75 kg. qd: Once daily; bid: Twice daily; qw: Once weekly; SVR: Sustained virologic response.

Citation: Zeng QL, Zhang JY, Zhang Z, Wang LF, Wang FS. Sofosbuvir and ABT-450: Terminator of hepatitis C virus? World J Gastroenterol 2013; 19(21): 3199-3206
URL: https://www.wjgnet.com/1007-9327/full/v19/i21/3199.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i21.3199